Open AccessPharmacokinetics of E -5-(2-Bromovinyl)-2′-Deoxyuridine in Mice
Author(s) -
Erik De Clercq,
J. Descamps,
P. De Somer,
Philip J. Barr,
A. S. Jones,
Richard Walker
Publication year - 1979
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.16.2.234
Subject(s) - deoxyuridine , pharmacokinetics , pharmacology , idoxuridine , drug , intraperitoneal injection , oral administration , chemistry , medicine , biochemistry , virology , dna , virus
The pharmacokinetics of the newly developed anti-herpes agent,E -5-(2-bromovinyl)-2′-deoxyuridine, was compared with that of the standard anti-herpes drug 5-iodo-2′-deoxyuridine. Both compounds were administered to mice at 100 mg/kg by either the intraperitoneal, subcutaneous, or oral route. The active blood drug levels achieved byE -5-(2-bromovinyl)-2′-deoxyuridine were considerably higher than those attained by 5-iodo-2′-deoxyuridine (serum peak concentrations: 40 to 100 and 4 to 10 μg/ml, respectively). Active blood drug levels could still be found 320 min after oral administration ofE -5-(2-bromovinyl)-2′-deoxyuridine.